GREY:ATBPF - Post by User
Comment by
PoorOpinionon Feb 19, 2018 3:50pm
108 Views
Post# 27584046
RE:RE:RE:RE:RE:RE:100
RE:RE:RE:RE:RE:RE:100Maybe the refs you're looking for are in the review I linked to earlier, this one has rat data for both H2S and NO releasing NSAIDS which look to perform equally well.
Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastroin- testinal-sparing effects of novel NSAIDs in rats with compro- mised mucosal defence. PLoS ONE. 2012;7:e35196. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.695.5587&rep=rep1&type=pdf StrikingMoose wrote: I wasn't attacking your post and I appreciate the comparable market value. Even I had not looked back to see who had partnered with Nicox for naproxincod. I remain hopeful that despite the theoretical GI effects of NO showing a benefical effect that we will see similar rodent-human translation as they did. I tried looking for the pre-clinical naproxincod data and can't find the study in question. Wish I could because it's got some nice pictures/charts showing placebo/naproxen/naproxincod and while there was indeed less severe lesions they were still there. Wallace's new way of measuring for gastric damage as a formula of lesion size and amount is a better value to read IMO compared to size of lesions/ulcers as they did with naproxincod and gives a truer picture of what to expect.... I hope.
Great to see they were able to get a name like AstraZeneca to partner up and buy in. I am hoping that they've already been working some existing relationships in this pre-pivotal time to get some preliminary negotiations started.
I remain hopeful as well that there is some big money waiting on the sidelines watching this, waiting for the trial results to come back positive or not in order to take sizeable positions. I hope everyone had a fantastic family day weekend :)